問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

MacKay Memorial Hospital

Division of Hematology & Oncology

Division of General Surgery

更新時間：2023-09-19

李芳
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李芳

List

51Cases

2025-07-01 - 2035-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-09-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-20 - 2037-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-12-01 - 2028-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-01-10 - 2028-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-01-31 - 2032-12-03

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-10-27 - 2028-02-18

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-10-15 - 2027-09-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2020-03-10 - 2025-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated1Sites

2018-12-01 - 2024-12-31

Phase III

Completed
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

  • Condition/Disease

    EARLY HER2-POSITIVE BREAST CANCER

  • Test Drug

    Atezolizumab

Participate Sites
5Sites

Terminated4Sites

王惠暢
China Medical University Hospital

Division of General Surgery

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB